semaglutide and levocarnitine compound Compounded FDA Ban on Compounded GLP-1

[DOI] [PubMed] [Google Scholar] 169.Bagchi D, Vuchetich PJ, Bagchi M, Hassoun EA, Tran MX, Tang L, Stohs SJ

International Journal of Obesity , 2023, 47.10: 883-892

Exenatide-Induced reduction in energy intake is associated with increase in hypothalamic connectivity

Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500